Lipoteichoic Acid Antikörper

Produktnummer ABIN7232846

Produktdetails anti-Lipoteichoic Acid Antikörper

Target: Lipoteichoic Acid (LTA)

Reaktivität: Gram Positive Bacteria

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser Lipoteichoic Acid Antikörper ist unkonjugiert

Applikation: ELISA

Verwendungszweck: Anti-Lipoteichoic Acid Mouse Monoclonal Antibody

Spezifität: This antibody reacts with lipoteichoic acid of Staph epidermidis, Hay strain, as well as clinical strains of Staph. epidermidis (types I, II, and III), Staph. aureus strains 5 and 8, Strep. pyogenes, Strep. fecaelis, and Strep. mutans. It does not react with peptido- glycan of Staph. aureus or peptidoglycan- rhamnose, nor does it react with pneumococcal polysaccharides. This antibody does not cross-react with E. coli or H. influenzae type B.

Kreuzreaktivität: Gram Positive Bacteria

Immunogen: Staphylococcus epidermidis, Hay strain (ATCC #55133).

Klon: 15711

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: ELISA: use at 0.1-1.0 μg/mL (optimized for LTA on solid phase).
Opsonization assay: use at 80-160 μg/mL (optimized for Staph. epidermidis, Hay strain).

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Rekonstitution: Dilute in PBS or medium that is identical to that used in the assay system.

Konzentration: Lot specific

Buffer: PBS, pH 7.4

Lagerung: -20 °C

Informationen zur Lagerung: This antibody is stable for at least one (1) year at -20°C. Avoid multiple freeze-thaw cycles.

Details zu Lipoteichoic Acid

Target: Lipoteichoic Acid (LTA)

Andere Bezeichnung: Lipoteichoic acid (LTA Produkte)

Synonyme: LT antikoerper, TNFB antikoerper, TNFSF1 antikoerper, lymphotoxin alpha antikoerper, LTA antikoerper

Substanzklasse: Chemical

Hintergrund: Lipoteichoic acid (LTA) is the major proinflammatory structure present within the cell wall layer of most gram-positive bacteria. It plays an important role in the initiation and progression of bacterial infection, inflammation, and septic shock. LTA induces several cytokines in vivo, and LTA and peptidoglycan (PepG) synergize to cause the induction of nitric oxide formation which can lead to multiple organ failure. Since LTA is also found in the cell walls of non-pathogenic gram-positive bacteria, it has been suggested that the structure of LTA , and its ability to synergize with PepG, determines the ability of a particular bacterium to cause septic shock.